AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24419513
Drug: Four-times-daily (4QD)
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-times-daily (4QD) administration of intra-venous (IV) BU
Trial: 17880350
Drug: Reduced appraisals
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced appraisals of past harm from baseline to end of treatment
Trial: 17880350
Drug: Increased harm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased harm appraisals from baseline to end of treatment
Trial: 17880350
Drug: Higher treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher treatment intensity and 12-step affiliation
Trial: 9806528
Drug: Bladder and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder and rectal volumes
Trial: 8548939
Drug: Methimazole treatment
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole treatment in TBII negative patients (Group A)
Trial: 8548939
Drug: Methimazole treatment
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole treatment in TBII positive patients (Group B)
Trial: 2173354
Drug: Long-term diazepam
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term diazepam treatment
Trial: 2173354
Drug: Acute i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute i.v. diazepam administration
Trial: 27882605
Drug: 6 mg/kgBM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kgBM caffeine (CAF)
Trial: 23998234
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of docosahexaenoic acid
Trial: 21430660
Drug: Tocilizumab infusion
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab infusion
Trial: 18180893
Drug: Dobell's solution
RxNorm normalized name: Dobell's Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobell's solution (Control)
Trial: 14745658
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (500 microg) twice daily
Trial: 11207464
Drug: Lidocaine 50
RxNorm normalized name: lidocaine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 50 mg with adrenaline
Trial: 11207464
Drug: Lidocaine 100
RxNorm normalized name: lidocaine 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 100 mg with adrenaline
Trial: 9435413
Drug: Active buccal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active buccal tablet containing 10 mg testosterone
Trial: 9435413
Drug: Buccal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal placebo tablet containing 3 mg pseudoephedrine HCl for taste matching
Trial: 8608205
Drug: 7-day treatment
RxNorm normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day treatment with chlormadinone acetate (CMA)
Trial: 8608205
Drug: 7-day treatment
RxNorm normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day treatment with acetazolamide (ACET)
Trial: 15616073
Drug: Nefopam 20
RxNorm normalized name: nefopam 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 20 mg
Trial: 31468673
Drug: Biyeom-go treatment
RxNorm normalized name: Go-dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biyeom-go treatment >3 times daily for a total of 4 weeks
Trial: 29908675
Drug: Cocoa powder
RxNorm normalized name: Cocoa powder
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa powder (30 g) and dark chocolate (50 g) daily for 1 week
Trial: 22120130
Drug: omega-3 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 group (6 g/d fish oil; n = 91)
Trial: 18416220
Drug: Zero-balanced ultrafiltration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zero-balanced ultrafiltration (ZBUF) (50 ml/kg) and conventional ultrafiltration (CUF)
Trial: 8073431
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 50-150 mg for five consecutive days in each treatment cycle
Trial: 2800898
Drug: 10% cyclosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% cyclosporin gel
Trial: 1090222
Drug: Paraldehyde (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraldehyde (10 ml rectally every 30 minutes)
Trial: 1090222
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg then 5 mg intravenously every 5 minutes)
Trial: 8609945
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of methotrexate (7.5 to 17.5 mg per week), sulfasalazine (500 mg twice daily), and hydroxychloroquine (200 mg twice daily)
Trial: 8609945
Drug: Methotrexate alone
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate alone (7.5 to 17.5 mg per week)
Trial: 8609945
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sulfasalazine (500 mg twice daily) and hydroxychloroquine (200 mg twice daily)
Trial: 3802705
Drug: Nitrendipine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (mean dose 32 mg/day)
Trial: 3802705
Drug: Acebutolol (414
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (414 mg/day)
Trial: 3802705
Drug: Nitrendipine and
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine and Acebutolol (both treatments)
Trial: 20413522
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg) intravenously at weeks 0, 2, 6, and 14
Trial: 16217977
Drug: 5-day telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-day telithromycin (800 mg once daily)
Trial: 16217977
Drug: 10-day amoxicillin-clavulanate
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day amoxicillin-clavulanate (500/125 mg 3 times daily)
Trial: 16217977
Drug: 10-day cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day cefuroxime axetil (250 mg twice daily)
Trial: 1693714
Drug: Felodipine (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (2.5, 5, and 10 mg b.i.d. for 2 weeks each)
Trial: 27951450
Drug: Standard-interval chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-interval chemotherapy
Trial: 26154930
Drug: CD34+ cell
RxNorm normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD34+ cell infusion (1.0 x 10^7 cells/vessel)
Trial: 26154930
Drug: CD34+ cell
RxNorm normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD34+ cell infusion (3.0 x 10^7 cells/vessel)
Trial: 20090145
Drug: Odontic Microsystem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odontic Microsystem treatment developed by R. Voll and R. Dale
Trial: 20090145
Drug: Complex treatment
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex treatment for patients with inner organ pathology
Trial: 16446328
Drug: Oral irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irinotecan (40 mg/m2/d MTD without cefixime; 60 mg/m2/d MTD with cefixime)
Trial: 16446328
Drug: Cefixime (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (8 mg/kg/d beginning 5 days before irinotecan and continuing throughout the course)
Trial: 16446328
Drug: Cefixime with
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime with oral irinotecan
Trial: 16446328
Drug: Oral irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irinotecan without cefixime
Trial: 16446328
Drug: Oral irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irinotecan with cefixime
Trial: 11423921
Drug: Red Wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red Wine Supplementation (240 ml/day)
Trial: 9243749
Drug: Hep B-3
RxNorm normalized name: amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hep B-3 vaccine containing both preS1- and preS2-derived proteins in addition to hepatitis B surface antigen
Trial: 7961239
Drug: Intra-arterial injection
RxNorm normalized name: METHOTREXATE 25 mg in 1 mL INTRA-ARTERIAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-arterial injection of naloxone HCl (60 micrograms)
Trial: 7961239
Drug: Systemic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic infusion of naloxone (4 mg)
Trial: 3591419
Drug: Low dosage,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage, titrated ECT
Trial: 27544007
Drug: 24-month dual-antiplatelet
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 24-month dual-antiplatelet therapy (DAPT)
Trial: 27544007
Drug: 6-month dual-antiplatelet
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month dual-antiplatelet therapy (DAPT)
Trial: 24352823
Drug: I-ONE therapy
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-ONE therapy administered postoperatively four hours per day for 60 days
Trial: 24352823
Drug: I-ONE therapy
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-ONE therapy
Trial: 20444849
Drug: Trastuzumab in
RxNorm normalized name: trastuzumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab in combination with capecitabine
Trial: 16625329
Drug: Surgery alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery alone (Treatment Arm A)
Trial: 16625329
Drug: Surgery, then
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery, then 1-hexylcarbamoyl-5-fluorouracil (Treatment Arm B)
Trial: 16625329
Drug: Surgery +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery + 1-hexylcarbamoyl-5-fluorouracil + mitomycin C (Treatment Arm D)
Trial: 16625329
Drug: Surgery, then
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery, then 1-hexylcarbamoyl-5-fluorouracil (Treatment Arm C)
Trial: 12794547
Drug: Two-dose intrapartum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose intrapartum neonatal nevirapine regimen
Trial: 10845685
Drug: Self-emulsifying vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-emulsifying vitamin E preparation
Trial: 10845685
Drug: Self-emulsifying vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-emulsifying vitamin E preparation and Natopherol
Trial: 1640362
Drug: Experimental formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental formulation of theophylline with 70% drum-dried corn starch (DDCS-70)
Trial: 1640362
Drug: Theo-dur (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theo-dur (reference sustained-release formulation)
Trial: 1640362
Drug: Experimental formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental formulation with 50% starch
Trial: 27782892
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (5×10^9 CFU B. lactis B94)
Trial: 27782892
Drug: Synbiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic treatment (5×10^9 CFU B. lactis B94 and 900 mg inulin)
Trial: 27782892
Drug: Prebiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic treatment (900 mg inulin)
Trial: 25251432
Drug: Low-dose continuous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose continuous (3 mg/kg q 24 hr)
Trial: 25251432
Drug: High-dose intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intermittent (three doses of 45 mg/kg q 6 hr repeated q 1 wk)
Trial: 25251432
Drug: Both low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both low-dose continuous and high-dose intermittent
Trial: 22133661
Drug: Vaginal ring
RxNorm normalized name: NuvaRing Vaginal Ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal ring (daily dose of 15 mcg ethinylestradiol/120 mcg etonogestrel)
Trial: 20663495
Drug: Oral contraception
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraception (OC) for 6 to 8 weeks before assisted reproduction treatment (ART)
Trial: 20663495
Drug: No pre-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pre-treatment with oral contraception (OC)
Trial: 20663495
Drug: Oral contraception
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraception (OC) for 6 to 8 weeks before ART
Trial: 14713317
Drug: Interviewer-administered CRQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-administered CRQ
Trial: 14713317
Drug: Self-administered CRQ
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered CRQ
Trial: 9678814
Drug: 1 week
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 week co-therapy with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Trial: 9678814
Drug: 2 week
RxNorm normalized name: Vimpat 2 Week Starter Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 week co-therapy with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Trial: 2591463
Drug: Alfuzosin 1
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 1 mg and 5 mg
Trial: 29564482
Drug: LY2140023 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2140023 (10, 40, and 160 mg)
Trial: 29564482
Drug: LY2979165 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2979165 (20 and 60 mg)
Trial: 26063068
Drug: Iron (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (300 mg ferrous sulfate) + 0.40 mg folate
Trial: 26063068
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + 0.40 mg folate
Trial: 8815481
Drug: Amikacin once
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin once daily (group A)
Trial: 8815481
Drug: Amikacin thrice
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin thrice daily plus carbenicillin (group B)
Trial: 8031165
Drug: UFT administration
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT administration
Trial: 1444488
Drug: FT‐E administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FT‐E administration
Trial: 8630719
Drug: Terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 60 mg bid
Trial: 2861767
Drug: Chlorpheniramine 4
RxNorm normalized name: chlorpheniramine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine 4 mg tid
Trial: 31084483
Drug: Monthly phone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly phone calls from a mental health professional
Trial: 30030699
Drug: Hazelnut and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hazelnut and cocoa spread (60 g)
Trial: 30030699
Drug: Milk chocolate
RxNorm normalized name: Meritene Milk Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk chocolate (60 g)
Trial: 11876700
Drug: Omeprazole, 20
RxNorm normalized name: Omeprazole, 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 20 mg in the morning
Trial: 11876700
Drug: Famotidine, 10
RxNorm normalized name: Famotidine, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine, 10 mg at bedtime
Trial: 11876700
Drug: Famotidine, 10
RxNorm normalized name: Famotidine, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine, 10 mg at 05.30 h
Trial: 11876700
Drug: Famotidine, 10
RxNorm normalized name: Famotidine, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine, 10 mg at bedtime and at 05.30 h
Trial: 10469339
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide releasing cream (mixed with nitrite and ascorbic acid, applied three times daily)
Trial: 10469339
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide releasing cream (high dose)
Trial: 10469339
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide releasing cream (48 h exposure)
Trial: 17164314
Drug: PTH(1-84) therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH(1-84) therapy alone
Trial: 17164314
Drug: PTH(1-84) therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH(1-84) therapy with alendronate
Trial: 21095149
Drug: PTH(1-84) therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH(1-84) therapy
Trial: 15088780
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of laboratory passaged wild-type influenza viruses
Trial: 15088780
Drug: Serum antibody
RxNorm normalized name: Pigeon serum antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum antibody
Trial: 15088780
Drug: Protective factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective factors in adults with lower levels of HI antibody
Trial: 15088780
Drug: Mucosal antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosal antibody measurement
Trial: 11938829
Drug: Heparin (Control)
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin (Control)
Trial: 30398646
Drug: Quercetin 3-glucoside
RxNorm normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quercetin 3-glucoside (160 mg/d)
Trial: 30398646
Drug: (−)-Epicatechin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (−)-Epicatechin (100 mg/d)
Trial: 24433317
Drug: Continuous wound
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous wound infusion of a local anaesthetic
Trial: 24433317
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous piritramide
Trial: 19846031
Drug: Ustekinumab (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (45 mg and 90 mg)
Trial: 16303729
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with benazepril 5 mg and losartan 25 mg
Trial: 14750091
Drug: Losartan (greater
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (greater dose)
Trial: 14750091
Drug: Benazepril (greater
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (greater dose)
Trial: 11581447
Drug: Erythropoietin (Epo),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (Epo), 400 U/kg 3 times weekly
Trial: 12879279
Drug: Phenylacetate (PAA)
RxNorm normalized name: phenylacetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylacetate (PAA) administered as a 30-min i.v. infusion at a dose of 1.8 g/m2
Trial: 12879279
Drug: Phenylacetate (PAA)
RxNorm normalized name: phenylacetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylacetate (PAA) administered as a 30-min i.v. infusion at a dose of 2.5 g/m2
Trial: 11393682
Drug: Heart rate-lowering
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart rate-lowering calcium antagonists (verapamil or diltiazem)
Trial: 3294122
Drug: Antidiarrhoeal agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiarrhoeal agents (long acting morphine sulphate)
Trial: 27144498
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy combined with conventional gel
Trial: 27144498
Drug: Conventional gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional gel only (Control)